Newsroom

Sorted by: Latest

-

Infleqtion to Present at Evercore TMT Conference

LOUISVILLE, Colo.--(BUSINESS WIRE)--Infleqtion (NYSE: INFQ), a global leader in quantum computing and quantum sensing powered by neutral-atom technology, announced that Matt Kinsella, CEO of Infleqtion, will present at the Evercore Technology, Media, and Telecommunications Conference taking place June 2-3, 2026, in San Francisco, CA. Conference Details: Evercore TMT Conference Date & Time: June 2, 2026, at 1:00 pm ET Format: Fireside Chat Presenter: Matt Kinsella, Infleqtion CEO A webcast o...
-

Fortress Investment Group Announces Acquisition of IPValue Management Group

NEW YORK--(BUSINESS WIRE)--Fortress Investment Group today announced the acquisition of IPValue Management Group (“IPValue”), one of the world’s leading intellectual property (“IP”) licensing companies. Funds managed by Fortress Investment Group affiliates (“Fortress”) led a group of investors that acquired the company. “Coming off our strongest year to date, we view Fortress as uniquely suited to support the next era of IPValue, as we continue to successfully execute our pipeline of new opport...
-

Fortress Investment Group、IPValue Management Group の買収を発表

ニューヨーク--(BUSINESS WIRE)--(ビジネスワイヤ) -- Fortress Investment Group は本日、世界有数の知的財産(IP)ライセンス企業の一つである IPValue Management Group(以下「IPValue」)の買収を発表しました。Fortress Investment Group 関連会社(以下「Fortress」)が運用するファンドが、同社を買収する投資家グループを主導しました。 IPValue の最高経営責任者(CEO)である John Lindgren 氏は次のように述べています。「当社は過去最高の業績を達成した直後にあり、今後の新たな事業機会の推進と商業化プログラムの拡大を進める中で 、Fortress はIPValue の次なる成長段階を支える理想的なパートナーであると考えています。25年にわたり、事実に基づくプロフェッショナルなビジネス交渉を通じて優れた成果を提供してきた実績により、IPValue は高く評価される IP 商業化パートナーとなっています。今回の投資によって実現するさらなる成長機会を大変楽しみにしていま...
-

Fortress Investment Group 宣布收購 IPValue Management Group

紐約--(BUSINESS WIRE)--(美國商業資訊)-- Fortress Investment Group 今日宣布收購全球領先的智慧財產(IP)授權公司之一 IPValue Management Group(簡稱「IPValue」)。本次收購由 Fortress Investment Group 關係企業(簡稱「Fortress」)管理之基金引領投資者完成。 IPValue 執行長 John Lindgren 表示:「在剛剛經歷公司成立以來表現最強勁的一年後,我們相信 Fortress 非常適合支持 IPValue 邁向下一個發展階段,協助我們繼續成功推進新的業務機會,並擴展商業化計畫的範圍。憑藉 25 年來透過專業且以事實為基礎的商業協商,持續為合作夥伴創造卓越的成果,IPValue 已成為備受青睞的 IP 商業化合作夥伴。我們對此次新投資所帶來的成長機會感到振奮。」 自 2001 年成立以來,IPValue 一直是全球頂尖科技企業IP管理與授權領域的領導者。公司已受託管理並策略性授權超過 20,000 件專利,涵蓋顯示器、半導體、記憶體、IT設備與服務以及網路通訊等廣泛技...
-

Axiom Bank Resolves OCC Formal Agreement, Enters New Era of Strength and Strategic Growth

ORLANDO, Fla.--(BUSINESS WIRE)--Axiom Bank, a nationally chartered bank headquartered in Orlando, Florida today announced that the Office of the Comptroller of the Currency (“OCC”) has terminated the Bank’s Formal Agreement dated October 3, 2024, effective April 29, 2026. This marks the successful completion of a comprehensive transformation that has reshaped the institution's governance, risk management infrastructure, and strategic direction. Axiom Bank meaningfully enhanced its risk manageme...
-

TPG to Present at the Morgan Stanley U.S. Financials Conference

SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)--TPG Inc. (NASDAQ: TPG), a leading global alternative asset management firm, announced today that Todd Sisitsky, President, is scheduled to present at the Morgan Stanley U.S. Financials Conference on Tuesday, June 9, 2026, at 1:00 p.m. ET. A live audio webcast of the discussion will be available on the Investor Relations section of TPG’s website at shareholders.tpg.com/events-presentations/events. For those unable to listen to the live webcast,...
-

Ollin Biosciences to Participate in Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences: 2026 Jefferies Global Healthcare Conference 1x1 Meetings: Tuesday, June 2 New York, NY Evercore 2026 Emerging Private Biotech Conference Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET Newport, RI About Ollin Biosciences Established in 2023, Ollin Bios...
-

Nielsen BioSciences Announces Positive Phase 3 Trial Results of CANDIN for the Treatment and Clearance of Common Warts

SAN DIEGO--(BUSINESS WIRE)--Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that its recently completed Phase 3 clinical trial of CANDIN® (Purified Candida albicans Antigen), the Company’s investigational immunotherapeutic therapy for the treatment and resolution of common warts (Verruca vulgaris) met its primary endpoint as well as key secondary endpoints. The topline results of the trial were presented earlier this month at t...
-

Member Satisfaction Holds Steady as Commercial Health Plans Focus on Improving Trust, Claims and Cost Stability

TROY, Mich.--(BUSINESS WIRE)--Despite significant investment by health plans in new digital tools and improved customer engagement, member satisfaction with commercial health plans has remained virtually unchanged for the past three years. According to the JD Power 2026 U.S. Commercial Member Health Plan Study,SM released today, the average overall satisfaction score for commercial health plans is 562 (on a 1,000-point scale), down one point from 2025 and three points from 2024. The findings re...
-

Echodyne Expands Public Safety Radar Applications Through Partnership with Axon

KIRKLAND, Wash.--(BUSINESS WIRE)--Echodyne, the radar platform company, today announced a partnership with Axon (Nasdaq: AXON), the global public safety technology leader, to support a joint focus activity on delivering best in class infrastructure for a range of homeland security and law enforcement UAS applications in the U.S and globally. Under the partnership, Echodyne’s advanced radar technology will continue supporting Axon’s growing ecosystem of public safety drone solutions, enhancing l...